Skip to content
Bored Studies
RecruitingPhase 3

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

AUG Therapeutics · NCT05754450

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 6 mo–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
2
US sites recruiting
1
Study start
April 10, 2023
Record last updated
May 1, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).

Being studied: AVTX-803

Conditions: Leukocyte Adhesion Deficiency

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subject must have completed protocol AVTX-803-LAD-301
  • Subject has biochemically and genetically proven LAD II (SLC35C1-CDG)

Exclusion Criteria

  • Subject has severe anemia defined as hemoglobin \<8.0 g/dL (\<4.9 mmol/L)
  • Subject has impaired renal function as defined by an eGFR \<90 mL/min
  • Subject has known or suspected intolerance or hypersensitivity to fucose or any ingredients of the investigational product
  • In the investigator's opinion, subject has a history of failure to respond to fucose at adequate dosing

Recruiting US locations

Study contacts (from the official record)

  • Jennifer Lin · 3052833827 · huiyil@Augtx.com
An Extension Study Assessing the Safety and Efficacy of AVTX-803… (NCT05754450) | Bored Studies